We hypothesize that GSC characteristics are not constrained to a small population of neoplastic CD133+ cells in GBM and that PDPN identifies a population of aggressive-treatment-resistant GSCs that may be contributing to poor GBM patient outcome. This evidence concerns the gene PDPN and glioblastoma.